Spliced to kill: RNA mis-splicing derived cancer neoantigens

Anurag V. Prabhu; Carla Azar-Koussa; Zahava Siegfried; Rotem Karni

doi:10.1016/j.trecan.2025.06.001

Spliced to kill: RNA mis-splicing derived cancer neoantigens

Anurag V. Prabhu, Carla Azar-Koussa, Zahava Siegfried, Rotem Karni^*

^*Corresponding author for this work

Department of Biochemistry and Molecular Biology

Research output: Contribution to journal › Short survey › peer-review

Abstract

One of the major challenges in using neoantigen-based approaches in cancer treatment is the identification of cancer-specific neoantigens, particularly those that are shared by patients. In a recent report, Kim et al. uncover a novel source of cancer neoantigens in splicing factor mutant myeloid malignancies. These mis-spliced neoantigens offer new opportunities for engineered TCR–T cell therapies and neoantigen-based vaccines.

Original language	English
Journal	Trends in Cancer
DOIs	https://doi.org/10.1016/j.trecan.2025.06.001
State	Accepted/In press - 2025

Bibliographical note

Publisher Copyright:
© 2025 Elsevier Inc.

Keywords

CAR-T
RNA processing
RNA splicing
immunotherapy
neoantigens

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2025.06.001

Cite this

@article{c09cb90fa9914e0c8d36a4dbdc19f88d,

title = "Spliced to kill: RNA mis-splicing derived cancer neoantigens",

abstract = "One of the major challenges in using neoantigen-based approaches in cancer treatment is the identification of cancer-specific neoantigens, particularly those that are shared by patients. In a recent report, Kim et al. uncover a novel source of cancer neoantigens in splicing factor mutant myeloid malignancies. These mis-spliced neoantigens offer new opportunities for engineered TCR–T cell therapies and neoantigen-based vaccines.",

keywords = "CAR-T, RNA processing, RNA splicing, immunotherapy, neoantigens",

author = "Prabhu, {Anurag V.} and Carla Azar-Koussa and Zahava Siegfried and Rotem Karni",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Inc.",

year = "2025",

doi = "10.1016/j.trecan.2025.06.001",

language = "אנגלית",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

}

TY - JOUR

T1 - Spliced to kill

T2 - RNA mis-splicing derived cancer neoantigens

AU - Prabhu, Anurag V.

AU - Azar-Koussa, Carla

AU - Siegfried, Zahava

AU - Karni, Rotem

PY - 2025

Y1 - 2025

N2 - One of the major challenges in using neoantigen-based approaches in cancer treatment is the identification of cancer-specific neoantigens, particularly those that are shared by patients. In a recent report, Kim et al. uncover a novel source of cancer neoantigens in splicing factor mutant myeloid malignancies. These mis-spliced neoantigens offer new opportunities for engineered TCR–T cell therapies and neoantigen-based vaccines.

AB - One of the major challenges in using neoantigen-based approaches in cancer treatment is the identification of cancer-specific neoantigens, particularly those that are shared by patients. In a recent report, Kim et al. uncover a novel source of cancer neoantigens in splicing factor mutant myeloid malignancies. These mis-spliced neoantigens offer new opportunities for engineered TCR–T cell therapies and neoantigen-based vaccines.

KW - CAR-T

KW - RNA processing

KW - RNA splicing

KW - immunotherapy

KW - neoantigens

UR - http://www.scopus.com/inward/record.url?scp=105008559200&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2025.06.001

DO - 10.1016/j.trecan.2025.06.001

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.shortsurvey???

C2 - 40541468

AN - SCOPUS:105008559200

SN - 2405-8033

JO - Trends in Cancer

JF - Trends in Cancer

ER -

Spliced to kill: RNA mis-splicing derived cancer neoantigens

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this